Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from kupffer cells

Molecular Therapy

Volumn 19, Issue 1, 2011, Pages 83-92

  Prill, Jan Michael ^a   Espenlaub, Sigrid ^a   Samen, Ulrike ^a   Engler, Tatjana ^a   Schmidt, Erika ^a   Vetrini, Francesco ^b   Rosewell, Amanda ^b   Grove, Nathan ^b   Palmer, Donna ^b   Ng, Philip ^b   Kochanek, Stefan ^a   Kreppel, Florian ^a  

^a UNIVERSITY OF ULM   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA MODIFICATION; GENETIC TRANSDUCTION; KUPFFER CELL; LIVER CELL; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMID; POINT MUTATION; PROTEIN BINDING; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ADENOVIRIDAE; MIRIDAE;

EID: 78650881455     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.229     Document Type: Article

References (41)

1. Schiedner, G, Hertel, S, Johnston, M, Dries, V, Van Rooijen, N and Kochanek, S (2003). Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 7: 35-43.
2. Xu, Z, Tian, J, Smith, JS and Byrnes, AP (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 82: 11705-11713.
3. Smith, JS, Xu, Z, Tian, J, Stevenson, SC and Byrnes, AP (2008). Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum Gene Ther 19: 547-554.
4. Vigant, F, Descamps, D, Jullienne, B, Esselin, S, Connault, E, Opolon, P et al. (2008). Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16: 1474-1480.
5. Waddington, SN, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
6. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488.
7. Danielsson, A, Elgue, G, Nilsson, BM, Nilsson, B, Lambris, JD, Tötterman, TH et al. (2010). An ex vivo loop system models the toxicity and effcacy of PEGylated and unmodifed adenovirus serotype 5 in whole human blood. Gene Ther 17: 752-762.
8. Wortmann, A, Vöhringer, S, Engler, T, Corjon, S, Schirmbeck, R, Reimann, J et al. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 16: 154-162.
9. Gao, JQ, Eto, Y, Yoshioka, Y, Sekiguchi, F, Kurachi, S, Morishige, T et al. (2007). Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Control Release 122: 102-110.
10. Corjon, S, Wortmann, A, Engler, T, Van Rooijen, N, Kochanek, S and Kreppel, F (2008). Targeting of adenovirus vectors to the LRP receptor family with the high-affnity ligand RAP via combined genetic and chemical modifcation of the pIX capsomere. Mol Ther 16: 1813-1824.
11. Koizumi, N, Yamaguchi, T, Kawabata, K, Sakurai, F, Sasaki, T, Watanabe, Y et al. (2007). Fiber-modifed adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 178: 1767-1773.
12. Brunetti-Pierri, N, Ng, T, Iannitti, DA, Palmer, DJ, Beaudet, AL, Finegold, MJ et al. (2006). Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther 17: 391-404.
13. Brunetti-Pierri, N, Stapleton, GE, Palmer, DJ, Zuo, Y, Mane, VP, Finegold, MJ et al. (2007). Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther 15: 732-740.
14. Schiedner, G, Hertel, S and Kochanek, S (2000). Effcient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 11: 2105-2116.
15. Espenlaub, S, Corjon, S, Engler, T, Fella, C, Ogris, M, Wagner, E et al. (2010). Capsomere-specifc fuorescent labeling of adenovirus vector particles allows for detailed analysis of intracellular particle traffcking and of the performance of bioresponsive bonds for vector capsid modifcations. Hum Gene Ther 21: 1155-1167.
16. Kreppel, F, Gackowski, J, Schmidt, E and Kochanek, S (2005). Combined genetic and chemical capsid modifcations enable fexible and effcient de- and retargeting of adenovirus vectors. Mol Ther 12: 107-117.
17. Fee, CJ and Van Alstine, JM (2004). Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug Chem 15: 1304-1313.
18. Waddington, SN, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
19. Kalyuzhniy, O, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008) Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U.S.A 105: 5483-5488.
20. Coyne, CB and Bergelson, JM (2005). CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev 57: 869-882.
21. Ziegler, RJ, Li, C, Cherry, M, Zhu, Y, Hempel, D, Van Rooijen, N et al. (2002). Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther 13: 935-945.
22. Kuzmin, AI, Finegold, MJ and Eisensmith, RC (1997). Macrophage depletion increases the safety, effcacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 4: 309-316.
23. Chuah, MK, Schiedner, G, Thorrez, L, Brown, B, Johnston, M, Gillijns, V et al. (2003). Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101: 1734-1743.
24. Bristol, JA, Shirley, P, Idamakanti, N, Kaleko, M and Connelly, S (2000). In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther 2: 223-232.
25. Croyle, MA, Yu, QC and Wilson, JM (2000). Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 11: 1713-1722.
26. Hofherr, SE, Mok, H, Gushiken, FC, Lopez, JA and Barry, MA (2007). Polyethylene glycol modifcation of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther 18: 837-848.
27. O'Riordan, CR, Lachapelle, A, Delgado, C, Parkes, V, Wadsworth, SC, Smith, AE et al. (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10: 1349-1358.
28. Kreppel, F and Kochanek, S (2008). Modifcation of adenovirus gene transfer vectors with synthetic polymers: a scientifc review and technical guide. Mol Ther 16: 16-29.
29. Doronin, K, Shashkova, EV, May, SM, Hofherr, SE and Barry, MA (2009). Chemical modifcation with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases effcacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther 20: 975-988.
30. Wortmann, A, Vöhringer, S, Engler, T, Corjon, S, Schirmbeck, R, Reimann, J et al. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 16: 154-162.
31. Mok, H, Palmer, DJ, Ng, P and Barry, MA (2005). Evaluation of polyethylene glycol modifcation of frst-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66-79.
32. Croyle, MA, Chirmule, N, Zhang, Y and Wilson, JM (2002). PEGylation of E1-deleted adenovirus vectors allows signifcant gene expression on readministration to liver. Hum Gene Ther 13: 1887-1900.
33. Campos, SK and Barry, MA (2006). Comparison of adenovirus fber, protein IX, and hexon capsomeres as scaffolds for vector purifcation and cell targeting. Virology 349: 453-462.
34. Fisher, KD, Stallwood, Y, Green, NK, Ulbrich, K, Mautner, V and Seymour, LW (2001). Polymer-coated adenovirus permits effcient retargeting and evades neutralising antibodies. Gene Ther 8: 341-348.
35. Morrison, J, Briggs, SS, Green, NK, Thoma, C, Fisher, KD, Kehoe, S et al. (2009). Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther 20: 239-251.
36. Lanciotti, J, Song, A, Doukas, J, Sosnowski, B, Pierce, G, Gregory, R et al. (2003). Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 8: 99-107.
37. Vigant, F, Descamps, D, Jullienne, B, Esselin, S, Connault, E, Opolon, P et al. (2008). Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther 16: 1474-1480.
38. Palmer, D and Ng, P (2003). Improved system for helper-dependent adenoviral vector production. Mol Ther 8: 846-852.
39. Palmer, DJ and Ng, P (2008). Methods for the production of helper-dependent adenoviral vectors. Methods Mol Biol 433: 33-53.
40. Kreppel, F, Biermann, V, Kochanek, S and Schiedner, G (2002). A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther 13: 1151-1156.
41. Van Rooijen, N and Sanders, A (1994). Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.